

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **VG LIFE SCIENCES INC.**

A Delaware Corporation

447 Broadway  
2nd Floor, Unit 103  
New York, NY 10013

---

435-387-5156

[www.vglscorp.com](http://www.vglscorp.com)

[info@vglscorp.com](mailto:info@vglscorp.com)

6719

### **Quarterly Report**

**For the Period Ending: March 31, 2022**  
(the "Reporting Period")

As of March 31, 2022, the number of shares outstanding of our Common Stock was:

5,118,853.726

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

2,768,782.721

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

2,768,782.721

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the

Yes: ☐ No: ☒

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

- VG Life Sciences Inc. since November 3, 2012
- Viral Genetics, Inc. until November, 2012
- 5 Star Living Online, Inc. until November, 2001
- HiTech Investment, Inc. until April, 1999

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

- Delaware, June 6, 1998, delinquent

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

- Going forward, the Company anticipates it will seek to conduct one or more of the following actions; recapitalization, merger, SEC registration statement, acquisition, reverse merger

The address(es) of the issuer's principal executive office:

The Company's principal place of business is 447 Broadway, 2nd Floor, Unit 103 New York, NY 10013

The address(es) of the issuer's principal place of business:

*Check box if principal executive office and principal place of business are the same address:* ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

**2) Security Information**

surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Trading symbol:	<u>VGLS</u>
Exact title and class of securities outstanding:	<u>Common Shares</u>
CUSIP:	<u>91822T101</u>
Par or stated value:	<u>\$0.0001</u>
Total shares authorized:	<u>20,000,000.000</u> as of date: <u>03/31/2022</u>
Total shares outstanding:	<u>5,118,853,726</u> as of date: <u>03/31/2022</u>
Number of shares in the Public Float <sup>2</sup> :	<u>4,420,291,348</u> as of date: <u>03/31/2022</u>
Total number of shareholders of record:	<u>314</u> as of date: <u>03/31/2022</u>

*All additional class(es) of publicly traded securities (if any):*

Trading symbol:	_____
Exact title and class of securities outstanding:	_____
CUSIP:	_____
Par or stated value:	_____
Total shares authorized:	_____ as of date: _____
Total shares outstanding:	_____ as of date: _____

#### Transfer Agent

Name: Liberty Stock Transfer, Inc.  
Phone: (732) 372-0707  
Email: info@libertystocktransfer.com  
Address: 788 Shrewsbury Ave., Suite 2163, Tinton Falls, NJ 07724

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes: ☒ No: ☐

### **3) Issuance History**

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### **A. Changes to the Number of Outstanding Shares**

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End: 1/01/2020 <u>Opening Balance</u> Common: 112,283,815 Preferred A: <u>10,000,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or canceled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance ? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
10/30/2020	issuance	11,116,097	CS	.01	Yes	Top Knot, Inc.- John Kellas	debt conversion	Unrestricted	3(a)10
11/18/2020	issuance	11,200,000	CS	.01	Yes	Mark Borden	debt conversion	Unrestricted	3(a)10
11/19/2020	issuance	250,000,000	CS	.0036	Yes	Endicott Holdings Group, LLC Mahmoud Jrab- Managing Member	Services	Restricted	n/a
11/20/2020	issuance	28,000,000	CS	.005	Yes	Mark Borden	debt conversion	Unrestricted	3(a)10
11/25/2020	issuance	28,000,000	CS	.005	Yes	Top Knot, Inc.- John Kellas	debt conversion	Unrestricted	3(a)10
12/11/2021	issuance	40,000,000	CS	.005	Yes	Mark Borden	debt conversion	Unrestricted	3(a)10
12/11/2020	issuance	20,000,000	CS	.005	Yes	Top Knot, Inc.- John Kellas	debt conversion	Unrestricted	3(a)10
1/11/2020	issuance	20,000,000	CS	.005	Yes	Intermarket Associates, LLC- Charles Abujudeh	debt conversion	Unrestricted	3(a)10
1/11/2020	issuance	20,000,000	CS	.005	Yes	OC Sparkle, Inc- Abraham Abu	debt conversion	Unrestricted	3(a)10
1/27/2020	issuance	50,000,000	CS	.005	Yes	Intermarket Associates, LLC- Charles Abujudeh	debt conversion	Unrestricted	3(a)10
02/03/2021	issuance	40,000,000	CS	.005	Yes	Top Knot, Inc.- John Kellas	debt conversion	Unrestricted	3(a)10
02/08/2021	Retired	-40,000,000	CS	.005	Yes	Mark Borden	debt conversion	Unrestricted	3(a)10
02/09/2021	issuance	50,000,000	CS	.005	Yes	OC Sparkle, Inc- Abraham Abu	debt conversion	Unrestricted	3(a)10

04/26/2021	issuance	63,419,391	CS	0.00365	Yes	Top Knot, Inc.- John Kellas	debt conversion	Unrestricted	3(a)10
06/29/2021	issuance	40,000,000	CS	.003	Yes	James Bursey	debt conversion	Unrestricted	3(a)10
07/15/2021	issuance	64,000,000	CS	0.0025	Yes	James Bursey	debt conversion	Unrestricted	3(a)10
07/20/2021	issuance	69,597,910	CS	0.003	Yes	MSW Projects Ltd-Bruce Bent	debt conversion	Unrestricted	3(a)10
07/21/2021	issuance	86,800,000	CS	0.003	Yes	James Bursey	debt conversion	Unrestricted	3(a)10
08/04/2021	issuance	95,477,304	CS	0.00275	Yes	James Bursey	debt conversion	Unrestricted	3(a)10
08/05/2021	issuance	104,929,557	CS	0.00275	Yes	MSW Projects Ltd-Bruce Bent	debt conversion	Unrestricted	3(a)10
08/16/2021	issuance	115,317,583	CS	0.0039	Yes	James Bursey	debt conversion	Unrestricted	3(a)10
08/25/2021	issuance	126,734,024	CS	0.0015	Yes	MSW Projects Ltd-Bruce Bent	debt conversion	Unrestricted	3(a)10
08/27/2021	issuance	139,280,692	CS	0.0015	Yes	James Bursey	debt conversion	Unrestricted	3(a)10
09/01/2021	issuance	153,069,481	CS	0.0027	Yes	MSW Projects Ltd-Bruce Bent	debt conversion	Unrestricted	3(a)10
09/20/2021	issuance	384,615,385	CS	0.0026	Yes	Paul Rachmuth	Legal Services Agreement	Restricted	N/A
12/09/2021	issuance	206,300,283	CS	0.0008	Yes	MSW Projects Ltd-Bruce Bent	debt conversion	Unrestricted	3(a)10
12/17/2021	issuance	226,724,011	CS	0.00077	Yes	MSW Projects Ltd-Bruce Bent	debt conversion	Unrestricted	3(a)10
12/23/2021	issuance	2,500,000	CS	0.0014	No	Axiom-Darren Bankston	services	Restricted	N/A
12/30/2021	issuance	249,417,188	CS	0.000565	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
01/07/2022	issuance	274,109,489	CS	0.0005	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
01/10/2022	issuance	150,000,000	CS	0.0005	Yes	Darling Capital- Yossi Levin	debt conversion	Unrestricted	3(a)10

01/12/2022	issuance	316,096,329	CS	0.0005	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
01/20/2022	issuance	347,389,865	CS	0.0005	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
02/03/2022	issuance	381,781,462	CS	0.00021	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
02/22/2022	issuance	419,577,827	CS	0.00017	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
03/09/2022	issuance	461,116,032	CS	0.00014	Yes	Bruce Bent	debt conversion	Unrestricted	3(a)10
Shares Outstanding on <u>March 31, 2022:</u> <u>Ending Balance:</u> Common: 5,118,853,726 Preferred A: <u>100,000,000</u>									

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

#### B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

#### 4) Financial Statements

A. The following financial statements were prepared in accordance with:

☒ U.S. GAAP

☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: Paul Strickland  
Title: Secretary  
Relationship to Issuer: Secretary

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

---

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

## **See Attached**

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

### **5) Issuer's Business, Products and Services**

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")
  - The Company is in the process of restructuring its business.
- B. Please list any subsidiaries, parents, or affiliated companies.
  - NA
- C. Describe the issuers' principal products or services.
  - Focused on becoming a real estate acquisitions, development, and value-added development company.

### **6) Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

- The Company's principal place of business is 447 Broadway, 2nd Floor, Unit 103, New York, NY 10013.
- \$120/year.

### **7) Company Insiders (Officers, Directors, and Control Persons)**

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**



Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Paul Strickland	Director & Secretary	Olympia, WA	N/A	N/A	N/A	Sole Director & Officers as of 06/02/2021
Selkirk Global Holdings, LLC- Paul Strickland, Sole Member, Sole Manager	Voting Control Shareholder >5%	Olympia, WA	95,858,282	Pref Series A	95.86%	95.86% total vote

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

- On November 3, 2020, the Company completed a 3(a)10 Court Ordered Settlement Agreement.

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name: Allen Tucci  
Firm: Archer & Greiner P.C.  
Address 1: Three Logan Square, 1717 Arch Street, Suite 3500  
Address 2: Philadelphia, PA 19103  
Phone: 215-246-3192  
Email: atucci@archerlaw.com

### Accountant or Auditor

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### Other Service Providers

Provide the name of any other service provider(s) that **assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Paul Strickland certify that:

1. I have reviewed this quarterly disclosure statement of VG Life Sciences, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: June 8, 2022

/s/ Paul Strickland (Officer's signature)

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, Paul Strickland certify that:

1. I have reviewed this quarterly disclosure statement of VG Life Sciences, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: June 8, 2022

/s/ Paul Strickland [Secretary's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

# VG LIFE SCIENCES INC.

## BALANCE SHEETS

(Unaudited)

	March 31, 2022	December 31, 2021
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Total Current Assets	-	-
<b>PROPERTY AND EQUIPMENT, NET</b>	-	-
<b>OTHER ASSETS</b>		
Total Other Assets	-	-
<b>TOTAL ASSETS</b>	<u>\$ -</u>	<u>\$ -</u>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 1,334,400	\$ 1,334,400
Accrued expenses	122,879	122,879
Due to related party	2,250	
Notes payable	1,849,145	2,609,001
Derivative liabilities	940,040	940,040
Total Current Liabilities	<u>4,248,714</u>	<u>5,006,320</u>
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>STOCKHOLDERS' DEFICIT</b>		
Preferred stock, 100,000,000 shares authorized, \$0.0001 par value; 9,715,443 and 9,715,443 issued and outstanding, respectively	972	972
Common stock, 20,000,000,000 shares authorized, \$0.0001 par value; 5,118,853,726 and 2,768,782,721 issued and outstanding, respectively	511,886	276,879
Additional paid-in capital	110,643,692	110,118,843
Noncontrolling interests	458,065	458,065
Deficit accumulated during the development stage	(115,863,329)	(115,861,079)
Total Stockholders' Deficit	<u>(4,248,714)</u>	<u>(5,006,320)</u>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b>	<u>\$ -</u>	<u>\$ -</u>

See accompanying notes to unaudited interim financial statements.

VG LIFE SCIENCES INC.  
STATEMENTS OF OPERATIONS  
(Unaudited)

	Three Months Ended March 31,	
	2022	2021
REVENUES	\$ -	\$ -
EXPENSES		
General and administrative expenses	2,250	-
Total expenses	2,250	-
LOSS FROM OPERATIONS	(2,250)	-
OTHER INCOME (EXPENSE)		
Interest expense	-	(75,710)
Total other income (expense)	-	(75,710)
NET LOSS	<u>\$ (2,250)</u>	<u>\$ (75,710)</u>
NET LOSS PER COMMON SHARE, BASIC AND DILUTED	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	<u>4,239,455,376</u>	<u>601,021,622</u>

See accompanying notes to unaudited interim financial statements.

VG LIFE SCIENCES INC.  
STATEMENTS OF STOCKHOLDERS' DEFICIT  
(Unaudited)

	Common Stock		Preferred Stock		Additional	Noncontrolling	Deficit	Total
	Shares	Amount	Shares	Amount	Paid-in capital	Interests	Accumulated During Development Stage	Stockholders' (Deficit)
Balance, December 31, 2019	112,283,815	\$ 11,229	9,715,443	\$ 972	\$ 104,939,032	\$ 492,473	\$ (113,165,583)	\$ (7,721,877)
Common stock issued for repayment of debt	98,316,097	9,832			370,249			380,081
Common stock issued for services	250,000,000	25,000						25,000
Net Loss attributable to noncontrolling interests, year ended December 31, 2020	-	-	-	-	-	(34,408)	-	(34,408)
Net loss for the year ended December 31, 2020	-	-	-	-	-	-	(1,455,150)	(1,455,150)
Balance, December 31, 2020	460,599,912	\$ 46,061	9,715,443	\$ 972	\$ 105,309,281	\$ 458,065	\$ (114,620,733)	\$ (8,806,354)
Common stock issued for repayment of debt	1,921,067,414	192,106			3,844,774			4,036,880
Common stock issued for Services	387,115,395	38,712			964,788			1,003,500
Net loss for the year ended December 31, 2021	-	-	-	-	-	-	(1,240,346)	(1,240,346)
Balance, December 31, 2021	2,768,782,721	\$ 276,879	9,715,443	\$ 972	\$ 110,118,843	\$ 458,065	\$ (115,861,079)	\$ (5,006,320)
Common stock issued for repayment of debt for the quarter ending March 31, 2022	2,350,071,005	235,007			524,849			759,856
Net loss for the quarter ended March 31, 2022	-	-	-	-	-	-	(2,250)	(2,250)
Balance, March 31, 2022	5,118,853,726	\$ 511,886	9,715,443	\$ 972	\$ 110,643,692	\$ 458,065	\$ (115,863,329)	\$ (4,248,714)

See accompanying notes to unaudited interim financial statements.

VG LIFE SCIENCES INC.  
STATEMENTS OF CASH FLOWS  
(Unaudited)

	Three Months Ended March 31,	
	2022	2021
Cash Flows From Operating Activities:		
Net loss	\$ (2,250)	\$ (75,710)
Adjustments to reconcile net loss to net cash used in operating activities:		
Increase in amount due to related party	2,250	
Increase in accrued interest		75,710
Net cash used in operating activities	-	-
Cash Flows From Financing Activities:		
Increase in notes payable		-
Net cash provided by financing activities	-	-
Increase (decrease) in Cash		-
Cash and cash equivalents, beginning of period		-
Cash and cash equivalents, end of period	\$ -	\$ -
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Cash paid during the period for:		
Interest	\$ -	\$ -
Income taxes	\$ -	\$ -

See accompanying notes to unaudited interim financial statements.

**VG LIFE SCIENCES INC.**  
**Notes to Financial Statements**  
**For the Three Months Ended March 31, 2022 and 2021**  
**(Unaudited)**

---

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

VG Life Sciences Inc. (the “Company” or “VGLS”), formerly Viral Genetics, Inc., was incorporated in California on July 11, 1995. The Company is engaged in research and development of therapeutic and diagnostic pharmaceutical and medical products. The Company was acquired by a publicly traded Delaware Corporation and became a reporting issuer on October 1, 2001. On November 5, 2001, the publicly traded company changed its name to Viral Genetics, Inc. The Company terminated registration with the SEC on March 24, 2009. The Company became a reporting issuer again on October 14, 2014. On November 26, 2012, the Company’s name was changed to VG Life Sciences, Inc. The Company’s fiscal year-end is December 31. The company terminated registration with the SEC on August 15, 2018.

**NOTE 2 - BASIS OF PRESENTATION**

The accompanying unaudited interim financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. The unaudited balance sheet as of March 31, 2022, unaudited statements of operations for the three months ended March 31, 2022 and 2021, and the unaudited statements of cash flows for the three ended March 31, 2022 and 2021 include all material adjustments, consisting only of normal recurring adjustments (unless otherwise discussed below), which management considered necessary for a fair presentation of the financial position and operating results for the periods presented. These unaudited financial statements are the representations of management. The notes to the accompanying unaudited consolidated financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States of America for complete consolidated financial statements.

**Going Concern**

As of March 31, 2022, the Company had an accumulated deficit of \$115,863,329 million and requires substantial additional funds to continue its research and development, to support its operations and to achieve its business development goals, the attainment of which are not assured. The Company has been able to satisfy certain liabilities with convertible indebtedness and common shares and enter into debt settlement arrangements, facilitated by third party financing, with vendors and creditors for substantial amounts of its various financial obligations. Convertible instruments have also been converted into equity. However, substantial indebtedness remains and substantial recurring losses from operations and additional liabilities continue to be incurred.

These factors and uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might incur in the event the Company cannot continue in existence. Management has designed plans for sales of the Company’s future pharmaceutical related products. Management intends to seek additional capital from new equity securities offerings, from debt financing and debt restructuring to provide funds needed to increase liquidity, fund internal growth and fully implement its business plan. However, management can give no assurance that these funds will be available in adequate amounts, or if available, on terms that would be satisfactory to the Company.

The timing and amount of the Company’s capital requirements will depend on a number of factors, including (i) the need for funds to support research and development, (ii) payment requirements to sustain patent and licensing rights, (iii) demand for new products and services, (iv) the availability of opportunities for international expansion through affiliations, (v) maintaining its status as a public company and supporting shareholder and investor relations, (vi) the need to establish and maintain current and new business relationships, and (vii) for other general corporate business purposes.

**NOTE 3 – DEBT SETTLEMENT**

Effective March 25, 2021, the Company entered into a 3(a)10 settlement of its convertible notes which had been assigned to a third party. The Company entered into a note payable agreement to pay an amount of \$5,883,380 in exchange for all of its convertible notes, accrued interest and expenses associated with transaction. During the three months ended March 31, 2022 common stock was issued for payment of the note payable in the amount of \$759,856. The balance outstanding as of March 31, 2022 is \$1,849,145.



**VG LIFE SCIENCES INC.**  
**Notes to Financial Statements**  
**For the Three Months Ended March 31, 2022 and 2021**  
**(Unaudited)**

---

**NOTE 4 - SUBSEQUENT EVENTS**

On April 26, 2022, the Company issued 506,766,519 million shares of its unrestricted common stock at .00015 in settlement of \$76,014.98 of the Company's outstanding debt.

On May 3, 2022, the Company issued 556,936,404 million shares of its unrestricted common stock at .0005 in settlement of \$66,832.37 of the Company's outstanding debt.

Management has evaluated all other activity since March 31, 2022 through the date the financial statements were issued and has concluded that no additional subsequent events have occurred that would require recognition in the Financial Statements or disclosure in the Notes to the Financial Statements.